You are here: Industry Insights > Zolgensma

News List

AveXis’ Zolgensma Aproved for Pediatric Patients with Spinal Muscular Atrophy contractpharma
June 14, 2019
The first and only gene therapy approved by the FDA for the treatment of SMA, including those who are pre-symptomatic at diagnosis.
Zolgensma: First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA) drugs
June 03, 2019
First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA).
FDA Approves Zolgensma (onasemnogene abeparvovec-xioi) Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy drugs
May 29, 2019
FDA Approves Zolgensma.
Novartis’ gene therapy Zolgensma gets FDA sign-off pharmaceutical-technology
May 29, 2019
Novartis subsidiary AveXis has received approval from the US Food and Drug Administration (FDA) for Zolgensma to treat children with spinal muscular atrophy (SMA).
FDA Approves First Gene Therapy Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy drugs
May 29, 2019
FDA Approves First Gene Therapy Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy.
Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve fiercepharma
May 29, 2019
Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer.
Zolgensma wins FDA green light in child SMA pharmatimes
May 28, 2019
The U.S. Food and Drug Administration (FDA) has approved Novartis’ Zolgensma (onasemnogene abeparvovec-xioi) at a cost of $2.1 milllion per treatment.
Novartis says it is ready to meet even 'unprecedented' demand for Zolgensma fiercepharma
May 12, 2019
Novartis’ initial jump into gene therapies with pioneering CAR-T drug Kymriah has run into manufacturing challenges that have slowed expansion in the U.S.
AveXis Presented Robust Data at AAN Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients drugs
May 08, 2019
AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)1 that showed positive results across a broad spectrum of patients with spinal muscular atrophy
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1 drugs
April 18, 2019
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1.

Previous page 1 2 3 4 Next page